JP2020500940A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500940A5 JP2020500940A5 JP2019551733A JP2019551733A JP2020500940A5 JP 2020500940 A5 JP2020500940 A5 JP 2020500940A5 JP 2019551733 A JP2019551733 A JP 2019551733A JP 2019551733 A JP2019551733 A JP 2019551733A JP 2020500940 A5 JP2020500940 A5 JP 2020500940A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- cell
- antibody
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662432334P | 2016-12-09 | 2016-12-09 | |
| US62/432,334 | 2016-12-09 | ||
| EP17179414.2 | 2017-07-03 | ||
| EP17179414 | 2017-07-03 | ||
| PCT/EP2017/082234 WO2018104554A1 (en) | 2016-12-09 | 2017-12-11 | Improved nk-based cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020500940A JP2020500940A (ja) | 2020-01-16 |
| JP2020500940A5 true JP2020500940A5 (https=) | 2021-01-21 |
Family
ID=60935785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551733A Pending JP2020500940A (ja) | 2016-12-09 | 2017-12-11 | 向上したｎｋ細胞ベースの治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230019381A1 (https=) |
| EP (2) | EP3551294B1 (https=) |
| JP (1) | JP2020500940A (https=) |
| KR (1) | KR20190110531A (https=) |
| CN (1) | CN110392595A (https=) |
| AU (1) | AU2017371514B2 (https=) |
| BR (1) | BR112019011461A2 (https=) |
| CA (1) | CA3045731A1 (https=) |
| ES (1) | ES2912173T3 (https=) |
| MX (1) | MX2019006597A (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112708675A (zh) * | 2020-12-25 | 2021-04-27 | 中山大学肿瘤防治中心 | 骨髓nk细胞联合mcl1抑制剂在抗白血病中的应用 |
| CN113267627B (zh) * | 2021-05-18 | 2022-09-20 | 首都医科大学附属北京地坛医院 | 用nk细胞上tigit和tim-3确定乙肝相关肝癌预后的系统 |
| CN114605560B (zh) * | 2022-03-30 | 2024-02-20 | 江苏蒙彼利生物科技有限公司 | 一种car-nk细胞及其制备方法与应用 |
| WO2024219474A1 (ja) * | 2023-04-21 | 2024-10-24 | 株式会社Logomix | Ｋｉｒ遺伝子クラスター領域、ｌｉｌｒ遺伝子クラスター領域およびｋｌｒ遺伝子クラスター領域のいずれか１以上の領域において欠失を有する細胞およびその製造方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0724532D0 (en) | 2007-12-17 | 2008-01-30 | Nat Univ Ireland | Trail variants for treating cancer |
| US20130058921A1 (en) * | 2009-10-30 | 2013-03-07 | Frits VAN RHEE | Use of autologous effector cells and antibodies for treatment of multiple myeloma |
| US9775921B2 (en) * | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| JP2015505669A (ja) * | 2011-11-25 | 2015-02-26 | シンガポール ヘルス サービシーズ ピーティーイー リミテッド | ナチュラルキラー／ｔ細胞リンパ腫（ｎｋｔｃｌ）の感受性予測、診断および治療 |
| EP3286211A1 (en) * | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
-
2017
- 2017-12-11 KR KR1020197019419A patent/KR20190110531A/ko not_active Ceased
- 2017-12-11 EP EP17825416.5A patent/EP3551294B1/en not_active Not-in-force
- 2017-12-11 CN CN201780076073.0A patent/CN110392595A/zh active Pending
- 2017-12-11 EP EP22156380.2A patent/EP4015043A1/en not_active Withdrawn
- 2017-12-11 MX MX2019006597A patent/MX2019006597A/es unknown
- 2017-12-11 JP JP2019551733A patent/JP2020500940A/ja active Pending
- 2017-12-11 BR BR112019011461A patent/BR112019011461A2/pt not_active IP Right Cessation
- 2017-12-11 AU AU2017371514A patent/AU2017371514B2/en not_active Ceased
- 2017-12-11 CA CA3045731A patent/CA3045731A1/en not_active Abandoned
- 2017-12-11 ES ES17825416T patent/ES2912173T3/es active Active
-
2022
- 2022-06-27 US US17/850,812 patent/US20230019381A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522592A5 (https=) | ||
| Jurczak et al. | Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma | |
| US11230598B2 (en) | Antibodies and methods for depleting regulatory bio cells and use in combination with immune checkpoint inhibitors | |
| JP2020500940A5 (https=) | ||
| MX2022011701A (es) | Anticuerpos anti-receptor de quimiocina 8 con motivo c-c (ccr8) para el tratamiento del cancer. | |
| TN2019000294A1 (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| HRP20220629T1 (hr) | Anti-cd73 antitijela i njihove upotrebe | |
| JP2015535691A5 (https=) | ||
| JP2020527144A5 (https=) | ||
| JP2017513478A5 (https=) | ||
| EP4512418A3 (en) | Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies | |
| JP2019513725A5 (https=) | ||
| JP2019503387A5 (https=) | ||
| JP2018518939A5 (https=) | ||
| JP2016527286A5 (https=) | ||
| JP2017507990A5 (https=) | ||
| JP2018516969A5 (https=) | ||
| PH12020551124A1 (en) | Bispecific antibody | |
| JP2016525117A5 (https=) | ||
| JP2017507936A5 (https=) | ||
| JP2019521169A5 (https=) | ||
| JP2022511337A5 (https=) | ||
| RS61901B1 (sr) | Neutralizacija inhibitornih puteva u limfocitima | |
| WO2020136145A3 (en) | Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies | |
| JP2021503954A5 (https=) |